Jubilant Pharmova Q1 FY27 Revenue Up 17% YoY to ₹2,229 Cr
Jubilant Pharmova reported Q1 FY27 results with revenue increasing 17% year-on-year to ₹2,229 Cr, driven by strong growth across all business segments, particularly CDMO Sterile Injectables. However, EBITDA saw an 11% decline to ₹268 Cr and PAT fell 45% to ₹56 Cr, mainly due to the unavailability of high-margin SPECT radiopharmaceutical products and increased operating expenses. The company expects EBITDA margins to improve from H2 FY27 as SPECT products become available. Key segments like Radiopharma and Radiopharmacy showed revenue growth, with significant investments planned for PET manufacturing network expansion. Progress was also noted in Allergy Immunotherapy, CDMO, Generics, and Proprietary Novel drugs businesses.
Key Highlights
- Revenue grew 17% YoY to ₹2,229 Cr, with broad-based segment growth.
- EBITDA declined 11% YoY to ₹268 Cr due to product mix and higher costs.
- PAT decreased 45% YoY to ₹56 Cr, impacted by lower operating profit and depreciation.
- SPECT radiopharmaceutical products expected to be available by H2 FY27, aiding margin recovery.
- Significant investment in PET manufacturing network expansion planned.
Price Impact
More from JUBLPHARMA